Idiosyncratic drug-induced liver injury (IDILI) is a rare but potentially severe adverse drug
reaction that should be considered in patients who develop laboratory criteria for liver injury …

This review encompasses the most important advances in liver functions and hepatotoxicity
and analyzes which mechanisms can be studied in vitro. In a complex architecture of nested …

The epidemiology and aetiology of drug‐induced liver injury (DILI) vary across different
countries and populations. Overall, DILI is rare in the general population but has become …

Drug-induced liver injury (DILI) is a patient-specific, temporal, multifactorial
pathophysiological process that cannot yet be recapitulated in a single in vitro model …

Drug-induced liver injury (DILI) can broadly be divided into predictable and dose dependent
such as acetaminophen (APAP) and unpredictable or idiosyncratic DILI (IDILI). Liver injury …

Because of a preconceived notion that eliminating reactive metabolite (RM) formation with
new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM …

Idiosyncratic drug-induced liver injury (DILI) is a type of hepatic injury caused by an
uncommon drug adverse reaction that can develop to conditions spanning from …

The liver is an organ with critical importance for drug treatment as the disposition and
response to a given drug is often determined by its hepatic metabolism. Patient-specific …

Idiosyncratic drug-induced liver injury (DILI) is a rare disease that develops independently of
drug dose, route, or duration of administration. Furthermore, idiosyncratic DILI is not a single …

BACKGROUND & AIMS: Drug-induced liver injury (DILI), especially from antimicrobial
agents, is an important cause of serious liver disease. Amoxicillin-clavulanate (AC) is a …